CEL-SCI Corp. 10-K Summary (Fiscal Year Ended Sept 30, 2016)
Business Context and Reporting Period
Company: CEL-SCI Corporation (CEL-SCI)
Reporting Period: Fiscal year ended September 30, 2016
Business Model: Biopharmaceutical company focused on immunotherapy for cancer and infectious diseases. The company has no commercial products and generates no product revenue.
Lead Asset: Multikine, an investigational immunotherapy for head and neck cancer (SCCHN) and HPV-related conditions. The company also develops LEAPS technology for influenza and rheumatoid arthritis.
Key Financial Metrics
| Metric | Fiscal 2016 | Fiscal 2015 |
|---|---|---|
| Revenue (Grant & Other) | $285,055 | $657,377 |
| Net Loss | $(11,466,498) | $(34,674,646) |
| Operating Expenses | $25,838,280 | $34,953,922 |
| Research & Development | $19,351,779 | $21,098,147 |
| General & Administrative | $6,486,501 | $13,855,775 |
| Gain on Derivative Instruments | $14,013,726 | $282,616 |
| Cash and Cash Equivalents (Sept 30, 2016) | $2,917,996 | $5,726,682 |
| Working Capital | $1,875,874 | $2,127,718 |
| Total Liabilities | $12,554,315 | $20,532,722 |
| Stockholders' Deficit | $(956,068) | $(5,085,119) |
Note: The significant reduction in net loss for 2016 is primarily driven by a $14.0 million non-cash gain on derivative instruments (warrant liabilities), not operational profitability.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $23.2 million compared to 2015, largely due to the $14.0 million gain on derivatives and a $7.4 million decrease in G&A expenses.
- G&A Expense Decrease: G&A expenses dropped significantly due to Lake Whillans Litigation Finance assuming payment of legal fees (~$4.4 million) and a reduction in share-based compensation costs (~$2.8 million).
- Derivative Liability: The fair value of derivative liabilities decreased from $13.7 million in 2015 to $8.4 million in 2016, resulting in the large gain.
- Cash Position: Cash decreased by approximately $2.8 million, driven by $23.1 million in net cash used for operating activities, partially offset by $21.4 million in proceeds from stock sales.
Guidance, Outlook, Risks, and Unusual Items
Critical Regulatory Event (Partial Clinical Hold): On September 26, 2016, the FDA placed CEL-SCI's pivotal Phase 3 clinical trial for Multikine (head and neck cancer) on a Partial Clinical Hold.
- Reasons: FDA cited an "unreasonable and significant risk of illness or injury," a misleading investigator brochure, and a deficient study protocol design.
- Impact: Enrollment of new patients is halted. The company submitted a response in November 2016. If the hold is not lifted or the study is deemed compromised, a new Phase 3 trial may be required, significantly delaying commercialization.
Liquidity and Going Concern:
- Substantial Doubt: The independent auditor (BDO USA, LLP) issued a report expressing substantial doubt about the company's ability to continue as a going concern due to recurring losses and future liquidity needs.
- Cash Runway: Management believes existing cash ($2.9 million) is sufficient to fund operations into the second quarter of fiscal 2017. Additional capital is required to complete the Phase 3 trial (estimated remaining cost: $12.1 million).
Legal Proceedings:
- Arbitration: CEL-SCI is in arbitration against its former CRO, inVentiv Health, seeking at least $50 million in damages for breach of contract and fraud. inVentiv has filed counterclaims seeking up to $24 million.
- SEC Investigation: The company is cooperating with a non-public SEC investigation regarding its financings and the arbitration.
Listing Status: The NYSE MKT notified the company of non-compliance with listing standards based on the June 30, 2016, 10-Q. A compliance plan is required by January 9, 2017, to avoid potential delisting.
Key Facts for Investor Verification
- FDA Partial Clinical Hold Status: Verify the current status of the FDA's review of CEL-SCI's response to the Partial Clinical Hold letter and whether enrollment has resumed.
- Liquidity Runway: Confirm the company's ability to raise additional capital to fund the estimated $12.1 million remaining cost of the Phase 3 trial and ongoing operations beyond Q2 2017.
- Derivative Liability Volatility: Understand that reported net income/loss is heavily influenced by the fair value changes of warrant liabilities, which do not reflect cash flow or operational performance.
- Arbitration Outcome: Monitor the progress of the arbitration against inVentiv Health, as a loss on counterclaims could materially impact liquidity.
- NYSE MKT Compliance: Verify if the company has submitted an acceptable compliance plan to the exchange to maintain its listing.